Literature DB >> 20193900

Treatment options for squamous cell cancer of the esophagus: a systematic review of the literature.

Michael Kranzfelder1, Peter Büchler, Konstanze Lange, Helmut Friess.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20193900     DOI： 10.1016/j.jamcollsurg.2009.12.010

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN： 1072-7515            Impact factor:   6.113


× No keyword cloud information.
  11 in total

1.  Maximizing early detection of esophageal squamous cell carcinoma via SILAC-proteomics.

Authors:  Kevin K Lee; Kristina Todorova; Anna Mandinova
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

2.  Quantitative measurement of contrast enhancement of esophageal squamous cell carcinoma on clinical MDCT.

Authors:  Rui Li; Tian-Wu Chen; Li-Ying Wang; Li Zhou; Hang Li; Xiao-Li Chen; Chun-Ping Li; Xiao-Ming Zhang; Ru-Hui Xiao
Journal:  World J Radiol       Date:  2012-04-28

3.  Moscatilin induces apoptosis and mitotic catastrophe in human esophageal cancer cells.

Authors:  Chien-An Chen; Chien-Chih Chen; Chien-Chang Shen; Hen-Hong Chang; Yu-Jen Chen
Journal:  J Med Food       Date:  2013-09-27       Impact factor: 2.786

Review 4.  Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients.

Authors:  Yuichiro Hiura; Shuji Takiguchi; Kazuyoshi Yamamoto; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Hiroshi Miyata; Yoshiyuki Fujiwara; Masaki Mori; Yuichiro Doki
Journal:  Int J Clin Oncol       Date:  2011-07-20       Impact factor: 3.402

5.  Lessons from Australia: human papillomavirus is not a major risk factor for esophageal squamous cell carcinoma.

Authors:  Jill Koshiol; Aimee R Kreimer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08       Impact factor: 4.254

6.  Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study.

Authors:  Yoshihiro Tanaka; Kazuhiro Yoshida; Yuichi Sanada; Shinji Osada; Kazuya Yamaguchi; Takao Takahashi
Journal:  Cancer Chemother Pharmacol       Date:  2010-09-28       Impact factor: 3.333

7.  Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma.

Authors:  Hitoshi Satomura; Masanobu Nakajima; Kinro Sasaki; Satoru Yamaguchi; Yasushi Domeki; Masakazu Takahashi; Hiroto Muroi; Tsukasa Kubo; Maiko Kikuchi; Haruka Otomo; Keisuke Ihara; Hiroyuki Kato
Journal:  Int Surg       Date:  2015-06

8.  Prognostic factors for esophageal squamous cell carcinoma--a population-based study in Golestan Province, Iran, a high incidence area.

Authors:  Karim Aghcheli; Haji-Amin Marjani; Dariush Nasrollahzadeh; Farhad Islami; Ramin Shakeri; Masoud Sotoudeh; Behnoush Abedi-Ardekani; Mohammad-Reza Ghavamnasiri; Ezzatollah Razaei; Elias Khalilipour; Samira Mohtashami; Yasha Makhdoomi; Rabea Rajabzadeh; Shahin Merat; Rasoul Sotoudehmanesh; Shahryar Semnani; Reza Malekzadeh
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

9.  Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.

Authors:  Yoshihiro Tanaka; Kazuhiro Yoshida; Atsuko Yamada; Toshiyuki Tanahashi; Naoki Okumura; Nobuhisa Matsuhashi; Kazuya Yamaguchi; Tatsuhiko Miyazaki
Journal:  Cancer Chemother Pharmacol       Date:  2016-02-20       Impact factor: 3.333

10.  THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Authors:  Ikuya Miki; Tsutomu Nakamura; Akiko Kuwahara; Motohiro Yamamori; Kohshi Nishiguchi; Takao Tamura; Tatsuya Okuno; Hideaki Omatsu; Shigeto Mizuno; Midori Hirai; Takeshi Azuma; Toshiyuki Sakaeda
Journal:  Int J Med Sci       Date:  2012-10-23       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.